T. Rowe Price Associates
ZOM

T. Rowe Price Associates’s Zomedica Corp. ZOM Stock Holding History

T. Rowe Price Associates’s Portfolio ZOM Stock Details ZOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-948,300
Closed -$139K – 3087
2024
Q1 		$139K Buy
948,300
+276,100
+41% +$38.6K ﹤0.01% 2715
2023
Q4 		$135K Buy
672,200
+186,800
+38% +$32.8K ﹤0.01% 2657
2023
Q3 		$82K Buy
485,400
+153,400
+46% +$29.8K ﹤0.01% 2700
2023
Q2 		$67K Hold
332,000
– – ﹤0.01% 2766
2023
Q1 		$71K Hold
332,000
– – ﹤0.01% 2743
2022
Q4 		$54K Buy
332,000
+144,000
+77% +$29.5K ﹤0.01% 2806
2022
Q3 		$40K Hold
188,000
– – ﹤0.01% 2863
2022
Q2 		$41K Hold
188,000
– – ﹤0.01% 2881
2022
Q1 		$63K Buy
188,000
+71,900
+62% +$23.5K ﹤0.01% 2904
2021
Q4 		$36K Sell
116,100
-390,400
-77% -$176K ﹤0.01% 2944
2021
Q3 		$265K Sell
506,500
-126,100
-20% -$74.4K ﹤0.01% 2622
2021
Q2 		$527K Buy
632,600
+244,800
+63% +$228K ﹤0.01% 2373
2021
Q1 		$613K Buy
+387,800
New +$634K ﹤0.01% 2275

Other funds holding ZOM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

T. Rowe Price Associates's ZOM Position: Q2 2024 in Review

T. Rowe Price Associates sold out of Zomedica Corp. (ZOM) in Q2 2024, closing a stake of 948,300 shares — an estimated $139K sold.

T. Rowe Price Associates first reported a position in ZOM in Q1 2021 and held it in 13 quarters. The position peaked at $613K in Q1 2021. 96 funds tracked by Wall St. Rank hold ZOM as of Q2 2024.

  • T. Rowe Price Associates reported no remaining Zomedica Corp. position as of Q2 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 948,300 Zomedica Corp. shares in Q2 2024, an estimated $139K.
  • T. Rowe Price Associates first reported a position in Zomedica Corp. in Q1 2021 and held it in 13 quarters.
  • T. Rowe Price Associates's Zomedica Corp. position peaked at $613K in Q1 2021.
  • 96 funds tracked by Wall St. Rank held Zomedica Corp. as of Q2 2024.

Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.